Whittier Trust Co. of Nevada Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,433 shares of the biopharmaceutical company’s stock after buying an additional 6,718 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Gilead Sciences were worth $7,839,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Welch Investments LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. purchased a new position in shares of Gilead Sciences in the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management grew its position in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.
In other news, insider John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Robin L. Washington sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $80.31, for a total value of $401,550.00. Following the completion of the sale, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at approximately $1,907,282.19. The disclosure for this sale can be found here. Insiders sold a total of 436,101 shares of company stock valued at $34,541,560 over the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same period in the prior year, the business earned $2.70 EPS. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. research analysts anticipate that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.13%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 65.52%.
Several equities analysts recently commented on GILD shares. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $88.80 to $76.00 in a research report on Tuesday, January 30th. Royal Bank of Canada restated a “buy” rating and set a $94.00 target price on shares of Gilead Sciences in a research report on Friday, February 23rd. BMO Capital Markets boosted their target price on Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research report on Thursday, February 8th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research report on Wednesday, January 17th. Finally, Credit Suisse Group cut Gilead Sciences from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $74.35 to $80.00 in a research report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and an average price target of $88.61.
ILLEGAL ACTIVITY NOTICE: “Whittier Trust Co. of Nevada Inc. Raises Holdings in Gilead Sciences, Inc. (GILD)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3296026/whittier-trust-co-of-nevada-inc-raises-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.